Table 1.

Characteristics of 606 patients with skull base chordoma tumors registered in SEER database (1973–2016).

Patients, n	606
Median age, years (range)	47 (0–92)
Mean age, years (± SD)	45.5 (19.3)
Median follow-up time, months (range)	59 (0–343)
Age (years)
<18	60 (9.9%)
18–39	169 (27.9%)
40–59	229 (37.8%)
60–79	133 (21.9%)
80+	15 (2.5%)
Year of Diagnosis	2007 median year (2006 mean)
1973–1999	119 (19.6%)
2000–2009	246 (40.6%)
2010–2016	241 (39.8%)
Gender
Male	332 (54.8%)
Female	274 (45.2%)
Race
White	486 (80.2%)
Black	33 (5.4%)
Others	87 (14.4%)
Married
Unmarried	182 (30%)
Married	404 (66.7%)
Unknown	20 (3.3%)
Registry
Low volume (<30 skull base patients)	153 (25.2%)
High volume (≥30 skull base patients)	453 (74.8%)
Histological Subtype
Chordoma	541 (89.3%)
Chondroid chordoma	64 (10.6%)
Dedifferentiated chordoma	1 (0.1%)
Primary Site
Bones of skull and face	440 (72.6%)
Brain	79 (13%)
Pituitary gland	34 (5.6%)
Others	53 (8.8%)
Disease Stage
Localized	262 (43.2%)
Regional	233 (38.4%)
Distant	58 (9.6%)
Unknown	53 (8.8%)
Surgery
No surgery performed	41 (6.7%)
STR	378 (62.4%)
GTR	187 (30.9%)
Radiation
No	305 (50.3%)
Yes	301 (49.7%)
Chemotherapy
No	592 (97.7%)
Yes	14 (2.3%)
Treatment Combination
None	24 (3.9%)
STR only	170 (28.1%)
STR+Radiation	180 (29.7%)
GTR only	111 (18.3%)
GTR+Radiation	104 (17.2%)
Radiation only	17 (2.8%)
Tumor Size (cm)
0–2	58 (9.6%)
2–4	197 (32.4%)
4–6	110 (18.2%)
>6	49 (8.1%)
Unknown	192 (31.7%)
Overall Survival (%)
5-Year Overall Survival	76.8
10-Year Overall Survival	61.8
Tumor-specific Survival (%)
5-Year Tumor-specific Survival	81.6
10-Year Tumor-specific Survival	69.9

GTR, gross total resection; STR, subtotal resection.